A Non Randomized Stratified Phase II Trial Evaluating Efficacy and Safety of Oxaliplatin in Combination With 5-Fluorouracil in Patients With Platinum-sensitive and Platinum-resistant Recurrent Ovarian Carcinoma
Evaluation of the safety and the efficacy of a combination of oxaliplatin and 5FU (Folfox)
in patients with ovarian carcinoma relapsing either after platinum-combined regimen.
The Folfox regimen is administered every 14 days. Evaluation of the toxicity is performed at
each cycle and evaluation of the efficacy every 4 cycles of chemotherapy.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective response rate
at 4 years
Veronique D'Hondt, MD,PhD
Jules Bordet Institute
Belgium: Federal Agency for Medicinal Products and Health Products